"Retina Health Center and the Macular Degeneration Research Center were established in 2002 by Dr. Alexander M. Eaton, a long-time Southwest Florida resident who has been practicing ophthalmology in Lee and Collier counties for 20 years. Dr. Eaton has been the principal investigator for numerous studies to prevent and treat macular degeneration, diabetic retinopathy, branch and central retinal vein occlusion."

During the past decade, Retina Health Center conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 6 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 5 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina Health Center" #1 sponsor was "Apellis Pharmaceuticals, Inc." with 3 trials, followed by "Hoffmann-La Roche" with 3 trials sponsored, "Kodiak Sciences Inc" with 2 trials sponsored, "OccuLogix" with 2 trials sponsored and "Alexander Eaton" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Health Center" #1 collaborator was "California Retina Consultants" with 3 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Konowal Vision Center" with 1 trials as a collaborator, "Northwestern University" with 1 trials as a collaborator and "Novartis Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Retina Health Center" are "Macular Degeneration" (8 trials), "Geographic Atrophy" (7 trials), "Age-Related Macular Degeneration" (1 trials), "Any Condition That Requires Ophthalmic Drops" (1 trials) and "Cataracts" (1 trials). Many other conditions were trialed in "Retina Health Center" in a lesser frequency.

Most popular intervention types in "Retina Health Center" are "Drug" (16 trials), "Other" (6 trials) and "Device" (3 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (6 trials), "Aflibercept" (2 trials), "KSI-301" (2 trials), "Lampalizumab" (2 trials) and "Ranibizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Retina Health Center" are 21 trials for "All" genders.

Currently, there are NaN active trials in "Retina Health Center". undefined are not yet recruiting, undefined are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Retina Health Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Health Center, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".